FDA Approves Daily Psoriasis Pill Clearing Most Patients’ Skin

The U.S. Food and Drug Administration approved a new oral therapy for moderate-to-severe plaque psoriasis on March 18, 2026. Johnson & Johnson announced the approval of ICOTYDE (icotrokinra), an IL-23 receptor antagonist taken once daily.

Clinical evidence and outcomes

The approval is based on the Phase 3 ICONIC program. That program enrolled about 2,500 patients across four pivotal trials.

In head-to-head studies, roughly 70% of patients achieved clear or almost clear skin by Investigator Global Assessment at Week 16. About 55% reached PASI 90 at the same time point.

Adverse reaction rates for treated patients were within 1.1% of placebo through Week 16. No new safety signals were reported through Week 52.

Industry coverage has used headlines such as FDA Approves Daily Psoriasis Pill Clearing Most Patients’ Skin.

What ICOTYDE is and how it is taken

ICOTYDE is the first targeted oral peptide designed to block the IL-23 receptor. It was jointly discovered by Protagonist and Johnson & Johnson.

The approved dose is 200 mg once daily, taken with water on an empty stomach. Patients should wait 30 minutes before eating.

Tablets can be dispersed in water for those with difficulty swallowing.

ICONIC clinical program

• ICONIC-LEAD (NCT06095115): placebo-controlled trial with PASI 90 and IGA co-primary endpoints.
• ICONIC-TOTAL (NCT06095102): assessed psoriasis in special areas such as scalp and genitals.
• ICONIC-ADVANCE 1 and 2 (NCT06143878, NCT06220604): head-to-head trials versus deucravacitinib and placebo.
• ICONIC-ASCEND (NCT06934226): trial including ustekinumab as an active comparator.

Additional studies are underway in psoriatic arthritis, ulcerative colitis, and Crohn’s disease.

Unmet need and expert perspectives

Psoriasis affects more than 8 million Americans and about 125 million people worldwide. Nearly one-quarter of patients have moderate-to-severe disease.

Experts noted the practical value of an oral, targeted option for patients who need systemic therapy. They highlighted that the drug may change conversations about treatment choices.

Johnson & Johnson executives described the approval as a significant advance in psoriasis care.

Safety, precautions, and side effects

ICOTYDE may increase the risk of infections. Health care providers should screen for tuberculosis before treatment.

Avoid live vaccines during therapy. Pregnant or breastfeeding patients should discuss risks with their providers.

Common side effects include fungal infection and tiredness. Patients should report new or worsening symptoms to their clinicians.

Access and patient support

Johnson & Johnson will offer a patient support program called ICOTYDE withMe. The program provides resources, Nurse Guide support, and cost assistance options.

Support is available regardless of insurance status. Patients and clinicians should consult prescribing information for full details.

Filmogaz.com will follow updates on prescribing guidance, ongoing trials, and post-approval safety monitoring. Healthcare providers can contact company resources for additional information.